DNASE1L3变异患者的狼疮肾炎模式与I型干扰素反应:三例报告
本文报告3例因DNASE1L3变异所致单基因系统性红斑狼疮(SLE)患儿,均表现为难治性肾小球肾炎并进展至肾衰竭,肾脏病理呈现膜性、内皮毛细血管性、外毛细血管性肾小球肾炎及血栓性微血管病等不同狼疮肾炎(LN)谱系模式。免疫荧光检测到肾小球内皮细胞表达I型干扰素(IFN-I)诱导的MXA蛋白,部分患者外周血干扰素刺激基因表达升高,所有患者血清DNA酶活性降低。提示DNASE1L3相关肾小球肾炎属于IFN-I介导的肾脏疾病谱,为IFN-I靶向治疗提供依据。
要点
- DNASE1L3变异可致单基因SLE,肾脏表现为难治性肾小球肾炎,可进展至肾衰竭。
- 肾脏病理可呈膜性、内皮毛细血管性、外毛细血管性肾小球肾炎及血栓性微血管病等LN谱系模式。
- 肾小球内皮细胞MXA表达及血清DNA酶活性降低提示IFN-I介导机制,支持IFN-I靶向治疗。
核心结论
- DNASE1L3相关肾小球肾炎可纳入IFN-I介导的肾脏疾病谱,为IFN-I靶向治疗提供依据。
研究设计与样本
- 病例报告,描述3例因DNASE1L3变异所致单基因SLE患儿的临床过程。
主要发现
- 3例患儿均发生难治性肾小球肾炎并导致肾衰竭,肾脏病理呈膜性、内皮毛细血管性、外毛细血管性肾小球肾炎及血栓性微血管病等LN谱系模式。
- 1例患者呈SLE与ANCA相关性血管炎重叠的混合表型。
- 免疫荧光检测到肾小球表达IFN-I诱导的MXA蛋白,尤以肾小球内皮细胞明显。
- 2例患者外周血干扰素刺激基因表达升高,所有3例患者血清DNA酶活性降低。
临床怎么用
- 对DNASE1L3变异相关难治性肾小球肾炎,应考虑IFN-I介导机制并评估IFN-I靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DNASE1L3 is an extracellular nuclease that digests chromatin released from apoptotic cells. DNASE1L3 variants impair the enzyme function, enhance autoantibody production and type I interferon (IFN-I) responses, and cause different autosomal recessive phenotypes ranging from hypocomplementemic urticarial vasculitis syndrome to full-blown systemic lupus erythematosus (SLE). Kidney involvement in patients with DNASE1L3 variants is poorly characterized. Herein, we describe the clinical course of 3 children with monogenic SLE due to DNASE1L3 variants who developed refractory glomerulonephritis leading to kidney failure. They had different renal histopathological patterns (ie, membranous, endocapillary, and extracapillary glomerulonephritis and thrombotic microangiopathy), all belonging to the lupus nephritis (LN) spectrum. One patient had a mixed phenotype, showing an overlap between SLE and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Using immunofluorescence, we detected glomerular expression of the IFN-I-induced human myxovirus resistance protein 1 (MXA), which was particularly evident in glomerular endothelial cells. Two of the patients had increased expression of interferon-stimulated genes in the peripheral blood, and all 3 patients had reduced serum DNAse activity. Our findings suggest that DNASE1L3-related glomerulonephritis can be included in the spectrum of IFN-I-mediated kidney disorders and provide the rationale for IFN-I-directed therapies in order to improve the poor outcome of this rare condition.
引用
- Volpi S, Angelotti ML, Palazzini G, et al. Lupus Nephritis Patterns and Response to Type I Interferon in Patients With DNASE1L3 Variants: Report of Three Cases. Am J Kidney Dis. 2024. PMID: 39059688. doi:10.1053/j.ajkd.2024.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。